Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing

The tumour suppressor p53 is mutated in cancer, including over 96% of high-grade serous ovarian cancer (HGSOC). Mutations cause loss of wild-type p53 function due to either gain of abnormal function of mutant p53 (mutp53), or absent to low mutp53. Massively parallel sequencing (MPS) enables increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Cole, Alexander J., Dwight, Trisha, Gill, Anthony J., Dickson, Kristie-Ann, Zhu, Ying, Clarkson, Adele, Gard, Gregory B., Maidens, Jayne, Valmadre, Susan, Clifton-Bligh, Roderick, Marsh, Deborah J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870633/
https://www.ncbi.nlm.nih.gov/pubmed/27189670
http://dx.doi.org/10.1038/srep26191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870633/
https://www.ncbi.nlm.nih.gov/pubmed/27189670
http://dx.doi.org/10.1038/srep26191

Ejemplares similares